Angiodynamics (ANGO) Common Equity (2016 - 2025)
Historic Common Equity for Angiodynamics (ANGO) over the last 17 years, with Q4 2025 value amounting to $176.3 million.
- Angiodynamics' Common Equity fell 558.71% to $176.3 million in Q4 2025 from the same period last year, while for Nov 2025 it was $176.3 million, marking a year-over-year decrease of 558.71%. This contributed to the annual value of $183.0 million for FY2025, which is 1100.07% down from last year.
- As of Q4 2025, Angiodynamics' Common Equity stood at $176.3 million, which was down 558.71% from $178.9 million recorded in Q3 2025.
- Angiodynamics' Common Equity's 5-year high stood at $454.9 million during Q1 2021, with a 5-year trough of $176.3 million in Q4 2025.
- In the last 5 years, Angiodynamics' Common Equity had a median value of $399.4 million in 2023 and averaged $328.8 million.
- Its Common Equity has fluctuated over the past 5 years, first skyrocketed by 332.41% in 2023, then crashed by 5404.86% in 2024.
- Angiodynamics' Common Equity (Quarter) stood at $432.4 million in 2021, then decreased by 5.65% to $408.0 million in 2022, then dropped by 1.65% to $401.2 million in 2023, then plummeted by 53.45% to $186.8 million in 2024, then decreased by 5.59% to $176.3 million in 2025.
- Its Common Equity stands at $176.3 million for Q4 2025, versus $178.9 million for Q3 2025 and $183.0 million for Q2 2025.